Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mourad Tayebi has a total of 138 co-authors. Here are the top co-authors by number of shared publications:

  • Clive Bate

    Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, North Mymms, Herts AL9 7TA, UK

    9 shared publications
  • Monique David

    School of Medicine, Western Sydney University, Campbelltown, Australia

    8 shared publications
  • Alun Williams

    Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Herts AL9 7TA, UK

    7 shared publications
  • Monique Antoinette David

    School of Medicine Western Sydney University Campbelltown New South Wales Australia

    7 shared publications
  • John Collinge

    MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

    6 shared publications
  • Umma Habiba

    6 shared publications

Latest Publications

  • Open Access

    Machine Learning and Multimodal Biomarker Discovery in Alzheimer’s Disease

    by Tariq Tayebi, Monique A. David, Mourad Tayebi

    Background/Objectives: The accelerating integration of machine learning (ML) with molecular, imaging, and physiological data is transforming Alzheimer’s disease (AD) research. Methods & Results: Recent studies demonstrate that multimodal, AI-assisted platforms can enhance early diagnosis, predict biomarker trajectories, and identify novel therapeutic targets. This mini-review covers the evolving AD diagnostic and biomarker frameworks, current therapeutic strategies including recently approved anti-amyloid immunotherapies, and advances from contemporary studies employing ML across diverse data streams, ranging from cerebrospinal fluid (CSF) and plasma proteomics to Raman spectroscopy, neuroimaging, transcriptomics, and microbiome signatures. Conclusions: Collectively, they illustrate how artificial intelligence (AI) has shifted A biomarker discovery from univariate to network-based inference, achieving clinically relevant accuracy while emphasizing model interpretability. We discuss biological insights, translational implications, and persisting challenges related to validation, bias, and regulatory integration.

  • Open Access

    Correction: Quansah et al. The Beneficial Effects of Lactobacillus Strains on Gut Microbiome in Alzheimer’s Disease: A Systematic Review. Healthcare 2025, 13, 74

    by Michael Quansah, Monique Antoinette David, Ralph Martins, Emad El-Omar, Silvana Mirella Aliberti, Mario Capunzo, Slade O. Jensen, Mourad Tayebi

  • Open Access

    Lactobacilli Probiotics Prevent Amyloid-Beta Fibril Formation In Vitro

    by Sanaa Harrass, Michael Quansah, Sachin Kumar, Michael Radzieta, Bhawantha Jayawardena, Christopher Jones, Monique David, Benjamin Heng, Liam D. H. Elbourne, Seth Amanquah, et al.

    Alzheimer’s disease (AD) is characterized by the buildup of extracellular aggregated amyloid-β (Aβ) peptides, following sequential enzymatic cleavage of amyloid precursor protein, along with intraneuronal accumulation of hyperphosphorylated Tau proteins and subsequent neuronal loss. Despite extensive research, the precise mechanisms underlying Aβ and Tau-mediated neurodegeneration remain elusive. Inhibiting protein aggregation has been a primary focus for mitigating neuronal toxicity. Probiotics have emerged as a promising preventative measure against cognitive decline in AD, with several in vivo and clinical trials demonstrating the efficacy of select bacterial strains in slowing AD progression. However, these studies lack direct molecular evidence on the effects of probiotics on Aβ aggregation kinetic. Inhibiting protein aggregation is key to reducing neuronal toxicity. While probiotics have shown promise in preventing cognitive decline in Alzheimer’s disease, supported by in vivo and clinical studies, direct molecular evidence of their impact on Aβ aggregation kinetics remains lacking. In this study, we conducted bioinformatic and physicochemical assessments, including molecular docking of proteins derived from 13 probiotic strains against Aβ and Tau, identifying four strains predicted to efficiently inhibit Aβ aggregation. Kinetic studies confirmed that both the probiotic formulation and its derived supernatant significantly inhibited the conversion of monomeric Aβ and Tau into aggregated forms. To explore bioavailability, we administered the probiotic formulation to healthy individuals and detected its presence in stool samples, demonstrating survival through the gastrointestinal tract. These findings suggest that specific probiotic strains may serve as therapeutic candidates for targeting Aβ and/or Tau aggregation, with further studies warranted to assess their potential clinical utility in AD.


  • Open Access

    Phylogeny and Molecular Characterisation of PRNP in Red-Tailed Phascogale (Phascogale calura)

    by Krisel De Dios, Sachin Kumar, Ehsan Alvandi, Utpal Kumar Adhikari, Monique Amtoinette David, Mourad Tayebi

    Background/Objectives: The normal cellular prion protein (PrPC) is a cell-surface glycoprotein, mainly localised in neurons of the central nervous system (CNS). The human PRNP gene encodes 253 amino acid residues of precursor PrPC. Several studies that investigated the role of PRNP and PrPC in placental mammals, such as humans and mice, failed to reveal its exact function. Methods: In this study, we sequenced and characterised the PRNP gene and PrPC of the marsupial, P. calura, as a strategy to gain molecular insights into its structure and physicochemical properties. Placentals are separated from marsupials by approximately 125 million years of independent evolution. Results: Standard Western blotting analysis of PrPC phascogale displayed the typical un-, mono-, and di-glycosylated bands recognized in placentals. Furthermore, we showed that phascogale PRNP gene has two exons, similar to all the marsupials and placentals of the PRNP genes studied. Of note, the phascogale PRNP gene contained distinctive repeats in the PrPC tail region comparable to the closely related Tasmanian devil (Sarcophilus harrisii) and more distantly related to the grey short-tailed opossum (Monodelphis domestica), common wombat (Vombatus ursinus), and Tammar wallaby (Macropus eugenii); however, its specific composition and numbers were different from placentals. Of importance, comparisons of the phascogale’s PrPC physicochemical properties with other monotremes, marsupials, and placentals confirmed the Monotremata–Marsupialia–Placentalia evolutionary distance. We found that the protein instability index, a method used to predict the stability of a protein in vivo (Stable: 40), showed that the PrPC of all marsupials tested, including phascogale, were highly stable compared with the birds, reptiles, amphibians, and fish that were shown to be highly unstable. However, the instability index predicted that all placental species, including human (Homo sapiens), mouse (Mus musculus), bank vole (Myodes glareolus), rhinoceros (Rhinocerotidae), dog (Canis lupus familiaris), flying fox (Pteropus vampyrus), whale (Physeter catodon), cattle (Bos taurus), and sheep (Ovis aries), were either slightly unstable or nearly unstable. Further, our analysis revealed that despite their predicted high PrPC stability, P. calura exhibited substantial N-terminal disorder (53.76%), while species with highly unstable PrPCs based on their instability index, such as Danio rerio, Oryzias latipes, and Astyanax mexicanus, displayed even higher levels of N-terminal disorder (up to 75.84%). These findings highlight a discrepancy between overall predicted stability and N-terminal disorder, suggesting a potential compensatory role of disorder in modulating prion protein stability and function. Conclusions: These results suggest that the high stability of marsupial prion proteins indicates a vital role in maintaining protein homeostasis; however more work is warranted to further depict the exact function.


  • Open Access

    The Beneficial Effects of Lactobacillus Strains on Gut Microbiome in Alzheimer’s Disease: A Systematic Review

    by Michael Quansah, Monique Antoinette David, Ralph Martins, Emad El-Omar, Silvana Mirella Aliberti, Mario Capunzo, Slade O. Jensen, Mourad Tayebi

    Background/Objectives: Growing evidence suggests that the gut–brain axis influences brain function, particularly the role of intestinal microbiota in modulating cognitive processes. Probiotics may alter brain function and behavior by modulating gut microbiota, with implications for neurodegenerative diseases like Alzheimer’s disease (AD). The purpose of this review is to systematically review the current literature exploring the effects of probiotic supplementation on gut microbiota and cognitive function in AD and mild cognitive impairment (MCI). Methods: A comprehensive literature search was conducted across PubMed/Medline, Embase, and Scopus to identify relevant randomized controlled trials (RCTs) from inception to 20 August 2024. The search focused on comparing outcomes between intervention and control/placebo groups. Data searches, article selection, data extraction, and risk of bias assessment were performed in accordance with Cochrane guidelines. Systematic Review Registration: PROSPERO registration no: CRD42023446796. Results: Data from four RCTs involving 293 Individuals (AD and MCI patients) receiving mainly Lactobacillus and Bifidobacterium strains showed some beneficial effects on cognitive function, altered gut microbiota composition, and positively affected metabolic biomarkers. However, variability in microbiota assessment across studies limits the interpretation of results. The limited number and quality of the existing studies make it difficult to draw definitive conclusions from the data. Additional high-quality research is clearly needed. Conclusions: Probiotics show promise as an adjunctive intervention for cognitive decline, but larger, long-term trials are needed to confirm their efficacy and clinical applicability in neurodegenerative diseases like AD.


  • Open Access

    Ethnogenetic-specific mutations in Alzheimer’s disease: A marker of clinical outcomes

    by Georgia Uebergang, Mourad Tayebi, Utpal K. Adhikari

    Alzheimer’s disease (AD) presents a substantial global health challenge, with its pathogenesis influenced by a complex interplay of genetic and molecular factors. Approximately 1% of AD cases are attributed to early onset autosomal dominant familial AD (fAD), with genetics contributing to about 70% of overall AD risk. Understanding the genetic basis and molecular mechanisms is paramount for early diagnosis and prognosis improvement. This study explores a previously underexplored area of fAD, examining how different mutations within the same gene, encoding a single protein, may influence the clinical features and progression of fAD subtypes. Our investigation focuses on distinct fAD subtypes — Iranian (T714A), Swedish (KM670/671NL), and Australian (L723P) — and their associated mutations within the C-terminus domain of amyloid precursor protein (APP). Through an extensive analysis of existing literature encompassing clinical severity, pathogenicity, neuropathology, and biological processes, we reveal critical insights into these fAD subtypes. Leveraging bioinformatics tools, we correlate the physicochemical properties of translated mutant proteins with clinical and neuropathological features. Notably, our findings demonstrate that mutations occurring between codons 714 and 717 of the APP gene share a higher similarity, resulting in lower root mean squared deviation scores. These mutations are associated with a broader spectrum of clinical symptoms, including myoclonus and seizures, and an earlier age of onset. Moreover, we observe a direct correlation between the location of genetic mutations on the protein sequence and specific physicochemical properties, clinical presentations, and neuropathological features among fAD subtypes. Mutations with higher structural similarity tend to manifest similar clinical and physical characteristics. While certain neuropathological findings correlate with an increasing epitope toxicity burden, our analysis indicates that epitope toxicity does not significantly impact clinical outcomes. In summary, our study provides novel insights into the heterogeneous nature of fAD subtypes, illuminating the intricate relationship between genetic mutations, physicochemical properties, and clinical manifestations. These findings offer a foundation for further research into tailored therapeutic approaches and personalized medicine for fAD.


  • Therapeutic anti‐amyloid β antibodies cause neuronal disturbances

    by Utpal Kumar Adhikari, Rizwan Khan, Meena Mikhael, Rachelle Balez, Monique Antoinette David, David Mahns, John Hardy, Mourad Tayebi

    Introduction: Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid‐related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen's Aduhelm/aducanumab (amino acids 3‐7 of the Aβ peptide). Similarly, Janssen/Pfizer's Bapineuzumab (amino acids 1‐5 of the Aβ peptide) and Roche's Gantenerumab (amino acids 2‐11/18‐27 of the Aβ peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively. The molecular mechanisms underlying ARIA caused by therapeutic anti‐Aβ antibodies remain largely unknown, however, recent reports demonstrated that therapeutic anti‐prion antibodies activate neuronal allergenic proteomes following cross‐linking cellular prion protein.Methods: Here, we report that treatment of human induced pluripotent stem cells‐ derived neurons (HSCN) from a non‐demented donor, co‐cultured with human primary microglia with anti‐Aβ1‐6, or anti‐Aβ17‐23 antibodies activate a significant number of allergenic‐related proteins as assessed by mass spectrometry.Results: Interestingly, a large proportion of the identified proteins included cytokines such as interleukin (IL)‐4, IL‐12, and IL‐13 suggesting a type‐1 hypersensitivity response. Following flow cytometry analysis, several proinflammatory cytokines were significantly elevated following anti‐Aβ1‐6, or anti‐Aβ17‐23 antibody treatment.Discussion: These results justify further and more robust investigation of the molecular mechanisms of ARIA during immunotherapy study trials of AD.HIGHLIGHTS: Allergenic‐related proteins are often linked with Alzheimer's disease (AD). We investigated the effects of amyloid beta (Aβ) immunotherapy on stem cell derived neurons and primary neuronal cells co‐cultured with microglia. Anti‐Aβ antibody treatment of neurons or neurons co‐cultured with microglia led to activation of a substantial number of allergenic‐related genes. These allergenic‐related genes are associated with endothelial dysfunction possibly responsible for ARIA.


  • Open Access

    A sequential deposition of amyloid beta oligomers, plaques and phosphorylated tau occurs throughout life in the canine retina

    by Umma Habiba, John Morley, Mark Krockenberger, Brian A. Summers, Mourad Tayebi

    Aims: Cerebral amyloid burdens may be found in otherwise cognitively intact adults, often not showing worsening deficits with passing years. Alzheimer’s transgenic rodents have been widely used to investigate this phenomenon, but a spontaneous disorder in other animals, such as dogs that cohabit with humans and thus may have some shared environmental risks, may contribute and offer opportunities not possible in the smaller laboratory animals. In animals, the spontaneous disorder most comparable to Alzheimer’s disease (AD) affects mature to aged dogs and is designated canine cognitive dysfunction. Motivated by AD, many studies have revealed that amyloid progressively accumulates in the canine central nervous system, including the retina. Here, we investigated whether deposits of amyloid and/or tau can be found in the canine retina of neurologically normal animals from the first year of life to the elderly. Suppose canine ocular amyloid and tau are present from early life. In that case, that raises the question of whether similar patterns of accumulation occur in man, whether as part of aging, AD, or other. Methods: This study used eye tissues from 30 dogs with a variety of ophthalmic or other orbital disorders, of which 7/30 were 1-2 years old. Tissues were subdivided into dogs of three different age groups: young (1-5 years old), middle (6-10 years old), and old (≥ 11 years old). Results: Following immunostaining of tissue sections with nanobodies against retinal Aβ1-40 and Aβ1-42 oligomers, and antibodies against Aβ plaques (Aβp) and hyperphosphorylated Tau (p-Tau), our investigations revealed that accumulation of Aβ1-40 and Aβ1-42 oligomers were widespread in the retina in all age groups. In contrast, Aβp were detected in the middle and old age groups but not in the young age group. Furthermore, p-Tau staining was observed in four old dogs only, while other dogs were p-Tau free. Interestingly, both Aβo and Aβp co-localized in the middle and old age groups of dogs. Moreover, diffuse granular p-Tau co-localized with intracellular Aβo in the old age group. Finally, we also observed co-localization of Aβo and Aβp in the retinal vasculature which might be similar to cerebral amyloid angiopathy associated with AD. Conclusion: As far as we know, the presence of amyloid and tau in the canine retina is hitherto unreported. If similar, early-in-life subclinical retinal deposits occur in a human cohort perhaps identified by AD genetic risk factors, following this group may offer the prospect of preclinical therapeutic intervention in imminent dementia, a strategy recognized as likely necessary to impact this burgeoning disorder.


  • Open Access

    Treatment of microglia with Anti-PrP monoclonal antibodies induces neuronal apoptosis in vitro

    by Utpal Kumar Adhikari, Elif Sakiz, Umma Habiba, Meena Mikhael, Matteo Senesi, Monique Antoinette David, Gilles J. Guillemin, Lezanne Ooi, Tim Karl, Steven Collins, et al.


  • Open Access

    Case Report: Synucleinopathy Associated With Phalaris Neurotoxicity in Sheep

    by Mourad Tayebi, Pedro Pinczowski, Umma Habiba, Rizwan Khan, Monique A. David, Brian A. Summers

    Chronic intoxication with tryptamine-alkaloid-rich Phalaris species (spp.) pasture plants is known colloquially as Phalaris staggers syndrome, a widely occurring neurological disorder of sheep, cattle, horses, and kangaroos. Of comparative interest, structurally analogous tryptamine-alkaloids cause experimental parkinsonism in primates. This study aimed to investigate the neuropathological changes associated with spontaneous cases of Phalaris staggers in sheep with respect to those encountered in human synucleinopathy. In sheep affected with Phalaris staggers, histological, immunohistochemical, and immunofluorescence analysis revealed significant accumulation of neuromelanin and aggregated α-synuclein in the perikaryon of neurons in the cerebral cortex, thalamus, brainstem, and spinal cord. Neuronal intracytoplasmic Lewy bodies inclusions were not observed in these cases of ovine Phalaris staggers. These important findings established a clear link between synucleinopathy and the neurologic form of Phalaris plant poisoning in sheep, demonstrated in six of six affected sheep. Synucleinopathy is a feature of a number of progressive and fatal neurodegenerative disorders of man and may be a common endpoint of such disorders, which in a variety of ways perturb neuronal function. However, whether primary to the degenerative process or a consequence of it awaits clarification in an appropriate model system.